Peter Attia on Peptides and Longevity Drugs, Fact-Checked
A source-checked look at where Peter Attia actually stands on NMN, rapamycin, metformin, GLP-1 drugs and BPC-157 — and where popular hype runs past the evidence.
-
-
Gary Brecka’s Peptide and Longevity Claims, Fact-Checked
A source-checked look at Gary Brecka’s claims on methylene blue, BPC-157, NAD+ and hydrogen — what the literature actually shows, and where certainty outruns data.
-
Three Semaglutides: How One Molecule Split Into Three Legal Categories
The GLP-1 shortage spawned a compounding boom. As the FDA winds it down, semaglutide is left as three distinct things that share a molecule’s regulatory story but not a legal status — and a research vial is the most misunderstood of them.
-
Is Research-Market Retatrutide Legit? The Drug, the Vial, and the Gap Between Them
Retatrutide is a real phase III triple agonist that produced some of the largest weight-loss figures in trial history. The vial sold on a research-chemical site is not that drug — and here is the honest distinction.
-
Why Silicon Valley Is Obsessed With Peptides
In a few short years, peptides went from obscure lab reagents to the most-discussed molecules in longevity and biohacking culture. A look at why now — and why the hype has outrun the data.
-
The Diary of a CEO Peptide Episode, Fact-Checked
On 20 April 2026, one of the world’s biggest podcasts told millions that Big Pharma is hiding a powerful peptide. We checked the science, line by line: where the episode is right, where it is clickbait, and where the honest evidence simply runs out.
-
Huberman’s peptide episode, fact-checked
On 1 June 2026, Huberman Lab spent a full episode on peptides. It was more careful than most of the internet. Here is what it covered — and how each claim holds up against the published research.
